Co-Diagnostics, Inc. Common Stock - Asset Resilience Ratio
Co-Diagnostics, Inc. Common Stock (CODX) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Co-Diagnostics, Inc. Common Stock PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Co-Diagnostics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See CODX net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Co-Diagnostics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CODX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Co-Diagnostics, Inc. Common Stock maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Co-Diagnostics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Co-Diagnostics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for Co-Diagnostics, Inc. Common Stock (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Co-Diagnostics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $24.74 Million | -- |
| 2024-12-31 | 41.89% | $26.81 Million | $64.00 Million | -3.88pp |
| 2023-12-31 | 45.77% | $43.63 Million | $95.32 Million | -1.58pp |
| 2022-12-31 | 47.36% | $58.29 Million | $123.09 Million | +46.57pp |
| 2021-12-31 | 0.78% | $1.26 Million | $160.03 Million | -5.30pp |
| 2020-12-31 | 6.09% | $4.34 Million | $71.24 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $4.66 Million | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more